Sign In
Buy TBPH
$16.86
+0.0100 (+0.0593%)
At Close: Jul 31, 2026
DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, random
Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped
11:32am, Sunday, 29'th Sep 2024
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
12:35pm, Wednesday, 04'th Sep 2024
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Tuesday, 27'th Aug 2024
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
12:01pm, Tuesday, 06'th Aug 2024
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
07:37pm, Monday, 05'th Aug 2024
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhon
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
07:01pm, Monday, 05'th Aug 2024
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
04:05pm, Monday, 05'th Aug 2024
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatr
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 25'th Jul 2024
DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
06:00am, Monday, 22'nd Jul 2024
DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, Augus
Best Momentum Stocks to Buy for July 15th
11:16am, Monday, 15'th Jul 2024
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
New Strong Buy Stocks for July 15th
08:21am, Monday, 15'th Jul 2024
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
Here's Why You May Invest in Theravance (TBPH) Stock Now
12:31pm, Wednesday, 26'th Jun 2024
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
10:55am, Friday, 21'st Jun 2024
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Tracking Seth Klarman's Baupost Group Holdings - Q1 2024 Update
06:46am, Monday, 20'th May 2024
pupunkkop This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Fo
